NCT04721977: A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic antibody, Tyrosine-kinase inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have received previous treatment with trastuzumab (Herceptin/trastuzumab, Perjeta/pertuzumab, & Kadcyla/T-DM1/)
Exclusions: Patients with known or suspected leptomeningeal disease (LMD); Patients with uncontrolled symptomatic brain metastases; Patients who have been previously treated with neratinib, afatinib, tucatinib, capecitabine, doxorubicin, epirubicin, mitoxantrone, idarubicin, liposomal doxorubicin

Comments are closed.

Up ↑